Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
about
Parenteral anticoagulation in ambulatory patients with cancerPrimary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapyPrimary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapyParenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationParenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationVenous thromboembolism in cancer patients: an underestimated major health problemCanadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.Cancer and Venous Thromboembolic Disease: A Review.Evolution of systemic therapy for advanced pancreatic cancer.The role of thromboprophylaxis in cancer patients: emerging data.Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management.Evidence-based guidance on venous thromboembolism in patients with solid tumoursSuppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin.Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial.Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival.Blood group determinates incidence for pancreatic cancer in GermanyThromboembolism in gastrointestinal cancers.Coagulation and cancer: biological and clinical aspects.Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms.Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer.Characterisation and risk assessment of venous thromboembolism in gastrointestinal cancers.Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.Parenteral anticoagulation in ambulatory patients with cancer.
P2860
Q22252972-F46E44BE-11BA-499C-A242-A3E2FCEB7DE9Q24194257-699A35AC-3325-470F-9578-EF40268D57F1Q24203644-381BEAB5-2462-4460-A11D-3886DE7FFA5FQ24234857-59228EC2-A6B3-4E99-AED6-E86794DFBED5Q24235112-205D7BDB-F1D6-4132-9F1B-CF6C42BAE356Q26852015-98B19E7E-F28C-4816-890A-220E9BD8072FQ33422297-3C6409F0-2561-4D41-AC85-0EDBA2FAED6DQ33439089-24B3F3D6-B388-4A59-9DBC-A2F09F807D73Q33557413-7F447691-B59A-4D3E-8AA7-469F457ACBABQ33625063-C0CD0D8E-7350-462C-8168-6051BDB5CFACQ33763866-68B0E2D8-2F49-40FF-BA91-24E53720B33FQ33763946-62ABD061-4BBE-4761-9BEF-4BB339E76D87Q33790809-93CA09E9-9B21-45CE-8C7E-C098912747F7Q34546366-17650FBA-80D9-42A9-B99C-83DCCEC11F36Q35123722-03376979-F853-461D-AF38-68C8A83C6096Q35174604-8F0A45BA-80A9-4F54-ACEB-7D62C838E737Q36160668-5160BE9C-A6FC-4069-A91C-93D8752484F1Q36871797-00FFF480-B281-44E2-8607-5E3F7156B705Q37076622-683BE6E1-107C-44AB-87F4-67F3CB0360ACQ38070918-1E89409A-9F8B-430A-B1FD-1CBA4A1F67DCQ38749053-FF7AF85F-4EA5-4096-9821-1EA0CB45DF55Q39375998-9312828E-EB97-4637-AB66-6109B3EB56B1Q42126706-9199752B-63E6-4493-8B83-509DC4CF6AD4Q47235947-078ECAAA-CE18-4E02-9A7F-25DE0713409DQ47551857-42B7F3F9-A926-48A2-843E-F6C8E146EA78
P2860
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Rationale and design of PROSPE ...... enoxaparin and chemotherapy).
@ast
Rationale and design of PROSPE ...... enoxaparin and chemotherapy).
@en
type
label
Rationale and design of PROSPE ...... enoxaparin and chemotherapy).
@ast
Rationale and design of PROSPE ...... enoxaparin and chemotherapy).
@en
prefLabel
Rationale and design of PROSPE ...... enoxaparin and chemotherapy).
@ast
Rationale and design of PROSPE ...... enoxaparin and chemotherapy).
@en
P2093
P2860
P356
P1433
P1476
Rationale and design of PROSPE ...... enoxaparin and chemotherapy).
@en
P2093
Andreas Hilbig
Bernd Dörken
Bernhard Opitz
Dörte Kauschat-Brüning
Hanno Riess
Helmut Oettle
Jens Stieler
Theo Scholten
Uwe Pelzer
P2860
P2888
P356
10.1186/1471-2407-8-361
P407
P577
2008-12-05T00:00:00Z
P5875
P6179
1035497409